Project Grant HT94252310030
Award Date
7/1/23
Completion Date
6/30/26
Dollars Obligated
$932K
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $724,500.00 to Duke University to conduct research targeted at eliminating residual breast cancer. The research aims to investigate dormancy-associated immune tolerance as a strategy to treat breast cancer. The award has a performance period from Mar 1, 2025 to Feb 29, 2028. This grant supports Duke University's ongoing efforts to advance innovative medical...
The Defense Health Agency awarded Duke University a $402,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The grant will support Duke University's research efforts to target the ferropotosis protection mechanism of serum to disable cancer metastasis. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for both...
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...
The Department of Defense's Defense Health Agency awarded a $1,182,931 Project Grant to Duke University on February 1, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a 3-year project focused on "NK CELL RESPONSE AS A CLINICAL DIFFERENTIATOR OF ENDOCRINE THERAPIES" that will be conducted at Duke University's Office of Research Administration Division. This research aims to improve understanding of the clinical implications of natural...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The Department of the Army Medical Command awarded Duke University a $482,890 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from April 1, 2022 to March 31, 2024 to target the oncogenomic function of the E2F8 transcription factor in lethal prostate cancer. Through this funding, Duke University researchers will investigate medical solutions for prostate cancer at the genomic level, with the aim of transforming healthcare for...